A preclinical model developed at UT Southwestern Medical Center that recapitulates a rare infant-onset form of diabetes ...

People live without their pancreas by taking medications and making good lifestyle choices. Learn about treatments and ...

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S.

Researchers have identified a new molecular target for treating pancreatic cancer. Scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for ...

Petrenko V, Sinturel F, Riezman H, Dibner C. Lipid metabolism around the body clocks. Progress in lipid research ...

Pat Gulhati, MD, PhD, discusses findings from a comprehensive analysis of genetic, immunological, and signaling pathway variations in pancreatic cancer.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival ...